One target, two evidence streams: Rituximab versus ocrelizumab in relapsing multiple sclerosis: A design-stratified systematic review, meta-analysis, and concordance assessment.

Rituxan (rituximab) - Roche

Ocrevus (ocrelizumab) - Roche

http://www.ncbi.nlm.nih.gov/pubmed/42777525

Ahmed Shaheen; Anas Mansour; Baraah Abu Alsel; Enas Kamal Abdalaziz Seyed; Mostafa Meshref; Ram Saha; Safya E Esmaeel; Yehia Nabil

Sep 24, 2026